An experimental gene-editing therapy from Crispr Therapeutics has successfully reduced high cholesterol levels in a small group of patients. This development marks a step toward broader applications of Crispr technology in treating heart disease.
Crispr Therapeutics has developed an experimental gene-editing therapy that shows promise for treating heart disease. The treatment, which uses Crispr, successfully slashed high cholesterol levels by half in a small number of people. This outcome represents progress in the wider use of gene editing for medical applications. The therapy targets high cholesterol, a key risk factor for heart disease. Details emerged in a report published on November 8, 2025.